Abstract
Although studies have shown that endothelial nitric oxide synthase (eNOS) homozygous knockout mice (eNOS−/−) develop left ventricular (LV) hypertrophy, well compensated at least to 24 wks, uncertainty still exists as to the cardiac functional and molecular mechanistic consequences of eNOS deficiency at later time-points. To bridge the gap in existent data, we examined whole hearts from eNOS−/− and age-matched wild-type (WT) control mice ranging in age from 18 to 52 wks for macroscopic and microscopic histopathology, LV mRNA and protein expression using RNA Dot blots and Western blots, respectively, and LV function using isolated perfused work-performing heart preparations. Heart weight to body weight (HW/BW in mg/g) ratio increased significantly as eNOS−/− mice aged (82.2%, P < 0.001). Multi-focal replacement fibrosis and myocyte degeneration/death were first apparent in eNOS−/− mouse hearts at 40 wks. Progressive increases in LV atrial natriuretic factor (ANF) and α-skeletal actin mRNA levels both correlated significantly with increasing HW/BW ratio in aged eNOS−/− mice (r = 0.722 and r = 0.648, respectively; P < 0.001). At 52 wks eNOS−/− mouse hearts exhibited basal LV hypercontractility yet blunted beta adrenergic receptor (βAR) responsiveness that coincided with a significant reduction in the LV ratio of phospholamban to sarcoplasmic reticulum Ca2+-ATPase-2a protein levels and was preceded by a significant upregulation in LV steady-state mRNA and protein levels of the 28 kDa membrane-bound form of tumor necrosis factor-alpha. We conclude that absence of eNOS in eNOS−/− mice results in a progressive concentric hypertrophic cardiac phenotype that is functionally compensated with decreased βAR responsiveness, and is associated with a potential cytokine-mediated alteration of calcium handling protein expression.
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig1_HTML.gif)
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig2_HTML.gif)
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig3_HTML.gif)
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig4_HTML.gif)
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig5_HTML.gif)
![](https://cdn.statically.io/img/media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12012-007-0028-y/MediaObjects/12012_2007_28_Fig6_HTML.gif)
Similar content being viewed by others
References
Huang, P. L., Huang, Z., Mashimo, H., Bloch, K. D., Moskowitz, M. A., Bevan, J. A., & Fishman, M. C. (1995). Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature, 377, 239–242.
Shesely, E. G., Maeda, N., Kim, H. S., Desai, K. M., Krege, J. H., Laubach, V. E., Sherman, P. A., Sessa, W. C., & Smithies, O. (1996). Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the USA, 93, 13176–13181.
Yang, X. P., Liu, Y. H., Shesely, E. G., Bulagannawar, M., Liu, F., & Carretero, O. A. (1999). Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension, 34, 24–30.
Ruetten, H., Dimmeler, S., Gehring, D., Ihling, C., & Zeiher, A. M. (2005). Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovascular Research, 66, 444–453.
Godecke, A., Heinicke, T., Kamkin, A., Kiseleva, I., Strasser, R. H., Decking, U. K., Stumpe, T., Isenberg, G., & Schrader, J. (2001). Inotropic response to beta-adrenergic receptor stimulation and anti-adrenergic effect of ACh in endothelial NO synthase-deficient mouse hearts. Journal of Physiology, 532, 195–204.
Gyurko, R., Kuhlencordt, P., Fishman, M. C., & Huang, P. L. (2000). Modulation of mouse cardiac function in vivo by eNOS and ANP. American Journal of Physiology–Heart and Circulatory Physiology, 278, H971–H981.
Vandecasteele, G., Eschenhagen, T., Scholz, H., Stein, B., Verde, I., & Fischmeister, R. (1999). Muscarinic and beta-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase. Nature Medicine, 5, 331–334.
Barouch, L. A., Cappola, T. P., Harrison, R. W., Crone, J. K., Rodriguez, E. R., Burnett, A. L., & Hare, J. M. (2003). Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. Journal of Molecular and Cellular Cardiology, 35, 637–644.
Barouch, L. A., Harrison, R. W., Skaf, M. W., Rosas, G. O., Cappola, T. P., Kobeissi, Z. A., Hobai, I. A., Lemmon, C. A., Burnett, A. L., O’Rourke, B., Rodriguez, E. R., Huang, P. L., Lima, J. A., Berkowitz, D. E., & Hare, J. M. (2002). Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature, 416, 337–339.
Li, W., Mital, S., Ojaimi, C., Csiszar, A., Kaley, G., & Hintze, T. H. (2004). Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. Journal of Molecular and Cellular Cardiology, 37, 671–680.
Colucci, W. S. (1997). Molecular and cellular mechanisms of myocardial failure. American Journal of Cardiology, 80, 15L–25L.
Siri, F. M., Nordin, C., Factor, S. M., Sonnenblick, E., & Aronson, R. (1989). Compensatory hypertrophy and failure in gradual pressure-overloaded guinea pig heart. American Journal of Physiology, 257, H1016–H1024.
Feldman, A. M., Weinberg, E. O., Ray, P. E., & Lorell, B. H. (1993). Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circulation Research, 73, 184–192.
Arai, M., Alpert, N. R., MacLennan, D. H., Barton, P., & Periasamy, M. (1993). Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circulation Research, 72, 463–469.
Marks, A. R. (2003). A guide for the perplexed: Towards an understanding of the molecular basis of heart failure. Circulation, 107, 1456–1459.
Chu, G., Ferguson, D. G., Edes, I., Kiss, E., Sato, Y., & Kranias, E. G. (1998). Phospholamban ablation and compensatory responses in the mammalian heart. Annals of the New York Academy of Sciences, 853, 49–62.
Frank, K. F., Bolck, B., Brixius, K., Kranias, E. G., & Schwinger, R. H. (2002). Modulation of SERCA: Implications for the failing human heart. Basic Research Cardiology, 97(Suppl 1), I72–I78.
Koss, K. L., Grupp, I. L., & Kranias, E. G. (1997). The relative phospholamban and SERCA2 ratio: A critical determinant of myocardial contractility. Basic Research Cardiology, 92(Suppl 1), 17–24.
Janczewski, A. M., Kadokami, T., Lemster, B., Frye, C. S., McTiernan, C. F., & Feldman, A. M. (2003). Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. American Journal of Physiology–Heart and Circulatory Physiology, 284, H960–H969.
Kilickap, M., Gurlek, A., Dandachi, R., Dincer, I., Tutkak, H., & Oral, D. (2004). Tumour necrosis factor-alpha in diastolic dysfunction. Acta Cardiology, 59, 507–510.
Kubota, T., Bounoutas, G. S., Miyagishima, M., Kadokami, T., Sanders, V. J., Bruton, C., Robbins, P. D., McTiernan, C. F., & Feldman, A. M. (2000). Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation, 101, 2518–2525.
Matsumori, A. (1996). Cytokines in myocarditis and cardiomyopathies. Current Opinion in Cardiology, 11, 302–309.
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., & Scheurich, P. (1995). The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell, 83, 793–802.
Mann, D. L. (2003). Stress-activated cytokines and the heart: From adaptation to maladaptation. Annual Review of Physiology, 65, 81–101.
Higuchi, Y., McTiernan, C. F., Frye, C. B., McGowan, B. S., Chan, T. O., & Feldman, A. M. (2004). Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation, 109, 1892–1897.
Dibbs, Z. I., Diwan, A., Nemoto, S., DeFreitas, G., Abdellatif, M., Carabello, B. A., Spinale, F. G., Feuerstein, G., Sivasubramanian, N., & Mann, D. L. (2003). Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation, 108, 1002–1008.
Krege, J. H., Hodgin, J. B., Hagaman, J. R., & Smithies, O. (1995). A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension, 25, 1111–1115.
Athirakul, K., Kim, H. S., Audoly, L. P., Smithies, O., & Coffman, T. M. (2001). Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney International, 60, 2324–2329.
Grupp, I. L., Subramaniam, A., Hewett, T. E., Robbins, J., & Grupp, G. (1993). Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. American Journal of Physiology, 265, H1401–H1410.
Jones, W. K., Grupp, I. L., Doetschman, T., Grupp, G., Osinska, H., Hewett, T. E., Boivin, G., Gulick, J., Ng, W. A., & Robbins, J. (1996). Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. Journal of Clinical Investigation, 98, 1906–1917.
Chu, G., Li, L., Sato, Y., Harrer, J. M., Kadambi, V. J., Hoit, B. D., Bers, D. M., & Kranias, E. G. (1998). Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo. Journal of Biological Chemistry, 273, 33674–33680.
Higuchi, Y., Chan, T. O., Brown, M., McTiernan, C. F., Jones, W. K., Feldman, A. M. (2006). Cardiac-specific blockade of NF-κB activation inhibits hypertrophy, restores Akt activity and improves survival in mice with TNF-α-induced heart failure. American Journal of Physiology–Heart and Circulatory Physiology, 290(2), H590–H598.
Flaherty, M. P., Takano, H., Murphree, S. G., Schultz, J. E., & Jones, W. K. (2000). Hypertensive-cardiac hypertrophy and induction of molecular markers in eNOS knockout mice. Absract. Journal of Molecular Cellular Cardiology, 32, A56–A16.
Sharp, B. R., Jones, S. P., Rimmer, D. M., & Lefer, D. J. (2002). Differential response to myocardial reperfusion injury in eNOS-deficient mice. American Journal of Physiology–Heart and Circulatory Physiology, 282, H2422–H2426.
Boluyt, M. O., O’Neill, L., Meredith, A. L., Bing, O. H., Brooks, W. W., Conrad, C. H., Crow, M. T., & Lakatta, E. G. (1994). Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circulation Research, 75, 23–32.
Bubikat, A., De Windt, L. J., Zetsche, B., Fabritz, L., Sickler, H., Eckardt, D., Godecke, A., Baba, H. A., & Kuhn, M. (2005). Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. Journal of Biological Chemistry, 280, 21594–21599.
Baker, D. L., Hashimoto, K., Grupp, I. L., Ji, Y., Reed, T., Loukianov, E., Grupp, G., Bhagwhat, A., Hoit, B., Walsh, R., Marban, E., & Periasamy, M. (1998). Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circulation Research, 83, 1205–1214.
Ji, Y., Lalli, M. J., Babu, G. J., Xu, Y., Kirkpatrick, D. L., Liu, L. H., Chiamvimonvat, N., Walsh, R. A., Shull, G. E., & Periasamy, M. (2000). Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. Journal of Biological Chemistry, 275, 38073–38080.
Han, X., Kubota, I., Feron, O., Opel, D. J., Arstall, M. A., Zhao, Y. Y., Huang, P., Fishman, M. C., Michel, T., & Kelly, R. A. (1998). Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the USA, 95, 6510–6515.
Chaudhri, B., Del Monte, F., Hajjar, R. J., & Harding, S. E. (2002). Interaction between increased SERCA2a activity and beta-adrenoceptor stimulation in adult rabbit myocytes. American Journal of Physiology–Heart and Circulatory Physiology, 283, H2450–H2457.
Haas, E., Grell, M., Wajant, H., & Scheurich, P. (1999). Continuous autotropic signaling by membrane-expressed tumor necrosis factor. Journal of Biological Chemistry, 274, 18107–18112.
Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hattler, B. G., & Simmons, R. L. (1992). Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 257, 387–389.
Bryant, D., Becker, L., Richardson, J., Shelton, J., Franco, F., Peshock, R., Thompson, M., & Giroir, B. (1998). Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation, 97, 1375–1381.
Kubota, T., McTiernan, C. F., Frye, C. S., Slawson, S. E., Lemster, B. H., Koretsky, A. P., Demetris, A. J., & Feldman, A. M. (1997). Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circulation Research, 81, 627–635.
Diwan, A., Dibbs, Z., Nemoto, S., DeFreitas, G., Carabello, B. A., Sivasubramanian, N., Wilson, E. M., Spinale, F. G., & Mann, D. L. (2004). Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation, 109, 262–268.
Acknowledgments
This study was supported by NIH R01HL-63034 (WKJ) and AHA 9930195N (WKJ). We gratefully acknowledge Dr. Paul Huang for the gift of the eNOS−/− mice and Drs. E.G. Kranias and G. Chu for their consultation and assistance with the measurement of PLB and SERCA2a protein levels and discussion of these results.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flaherty, M.P., Brown, M., Grupp, I.L. et al. eNOS Deficient Mice Develop Progressive Cardiac Hypertrophy with Altered Cytokine and Calcium Handling Protein Expression. Cardiovasc Toxicol 7, 165–177 (2007). https://doi.org/10.1007/s12012-007-0028-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-007-0028-y